NCT04356846View on ClinicalTrials.gov

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
Interventions
DRUG

LP-108 tablet

Taken orally within 30 minutes after a meal at the designated dose, once daily.

Trial Locations (1)

210000

RECRUITING

the First Affiliated Hospital of Nanjing Medical University, Nanjing

Sponsors

Collaborators (1)

Newave Pharmaceutical Inc
All Listed Sponsors
collaborator

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY

collaborator

Newave Pharmaceutical Inc

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT04356846 - A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | Biotech Hunter | Biotech Hunter